FIELD: medicine.
SUBSTANCE: invention can be used for treating early breast cancer (BC) involving a radical mastectomy. To this effect, blood in an amount of 8-10 ml is sampled before the surgical intervention and on the first day following the surgical intervention to detect tumour cells. If the blood is found to contain circulating tumour cells on the first postoperative day with a zero level, the therapeutic setting is added with early postoperative FAC-based polychemotherapy.
EFFECT: invention enables assessing the activity of the tumour process accompanying BC and planning the further therapeutic approach.
1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ASSESSMENT OF TUMOUR SENSITIVITY TO CHEMOTHERAPY OF PATIENTS WITH LOCALLY ADVANCED BREAST CANCER | 2015 |
|
RU2616532C1 |
| METHOD OF DETERMINING THE CONVERSION OF THE MOLECULAR BIOLOGICAL SUBTYPE OF THE TOTALITY OF CIRCULATING TUMOR CELLS RELATIVE TO THE MOLECULAR BIOLOGICAL SUBTYPE OF THE PRIMARY TUMOR IN PATIENTS WITH BREAST CANCER | 2022 |
|
RU2797698C1 |
| METHOD OF PREDICTING HEMATOGENOUS METASTASIS IN INVASIVE CARCINOMA OF NONSPECIFIC TYPE OF MAMMARY GLAND BASED ON DETERMINATION OF DIFFERENT POPULATIONS OF CIRCULATING TUMOR CELLS IN BLOOD BEFORE TREATMENT | 2018 |
|
RU2678202C1 |
| METHOD FOR PREDICTION OF HEMATOGENOUS METASTASIS IN INVASIVE BREAST CARCINOMA | 2021 |
|
RU2787170C1 |
| METHOD OF PREDICTING RESISTANCE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER | 2022 |
|
RU2802671C1 |
| METHOD FOR CALCULATING THE PERIOD OF DISTANT METASTASIS IN PATIENTS WITH COLON CANCER AND RECTOSIGMOID JUNCTION | 2022 |
|
RU2782149C1 |
| METHOD FOR PREDICTING THE RISK OF AN UNFAVORABLE OUTCOME OF COLON AND RECTOSIGMOID CANCER | 2021 |
|
RU2772207C1 |
| METHOD FOR DIAGNOSING BREAST CANCER BY LEVEL OF EXPRESSION OF IL-10 AND/OR IL-17 MRNA IN BLOOD PLASMA | 2020 |
|
RU2752971C1 |
| METHOD FOR PREDICTING THE RISK OF POOR TUMOR RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH INVASIVE BREAST CANCER | 2018 |
|
RU2682967C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING DISTANT METASTASES IN PATIENTS WITH OPERABLE FORMS OF BREAST CANCER WITH METASTASES IN REGIONAL LYMPH NODES | 2020 |
|
RU2733697C1 |
